Releas

Halozyme Therapeutics' Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society

- Co-Injection of rHuPH20 with Humira Estimated to Increase theMaximal Steady State Subcutaneous Bioavailability from 64% to 100%- SAN DIEGO, July 09, 2007 /PRNewswire-FirstCall/ -- HalozymeTherapeutics, Inc. , a biopharmaceutical company developing andcommercializing recombinant human enzymes, today announced thatfinal results of the Enhanze(TM) Technology clinical trialdemonstrating im...

Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia

ROCHESTER, Minn., July 2, 2007-Women with at least three sites ofcellular atypia in breast tissue are nearly eight times more likelythan average women to develop breast cancer, according to findingsof a Mayo Clinic Cancer Center led study of women with atypicalhyperplasia. The findings are published in the July 1 issue of theJournal of Clinical Oncology. Several previous studies have show...

Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company

Statement by Sandra C. Raymond, President & CEO of the LupusFoundation of America, Inc. WASHINGTON, June 27, 2007 /PRNewswire-USNewswire/ -- The LupusFoundation of America, Inc. and more than 1.5 million Americanswith lupus have been awaiting the preliminary findings of the PhaseIII clinical trials for CellCept(R), a potential treatment forlupus kidney disease being tested by Aspreva...

An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes

CHICAGO--(BUSINESS WIRE)--Jun 25, 2007 - New data from aninvestigational study released at the American Diabetes Association(ADA) 67th Annual Scientific Sessions showed that initialcombination therapy with Januvia(TM) (sitagliptin) and metformindemonstrated significant improvement in markers of beta cellfunction in patients with type 2 diabetes. Pancreatic islet betacell function determines...

Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes

Data Also Support Drug's Efficacy at Improving Glycemic Control andReducing Diabetic Cardiovascular Complications CHICAGO, Ill., June 23, 2007 /PRNewswire/ -- VeroScience, LLC,in conjunction with its commercialization partner S2 Therapeutics,Inc., reported today the results of its Phase IIIb clinical trialsupporting the overall and cardiovascular safety of Cycloset(TM) (Aquick release for...

Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes

CHICAGO--(BUSINESS WIRE)--Jun 23, 2007 - Late breaking datapresented at the American Diabetes Association (ADA) 67th AnnualScientific Sessions showed that, when used investigationally asinitial therapy, JANUVIA(TM) (sitagliptin) in combination withmetformin provided significant glycemic improvement and wasgenerally well tolerated over 54 weeks in patients with type 2diabetes. Additional new...

VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions

TIVERTON, R.I., June 18, 2007 /PRNewswire/ -- VeroScience, LLC,a privately held biotechnology and healthcare product developmentcompany, announced today that its late-breaking abstract has beenaccepted as a poster presentation at the 67th Scientific Sessionsof the American Diabetes Association in Chicago, Ill. The abstract,entitled, "Effects of Timed Cycloset(TM) (A Quick ReleaseFormulat...

Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma

LEXINGTON, Mass.--(BUSINESS WIRE)--Jun 12, 2007 - CriticalTherapeutics, Inc. (Nasdaq: CRTX) today announced the publicationof data from a pivotal Phase III clinical trial of ZYFLO CR(TM)(zileuton) extended-release tablets in the June 2007 issue of theJournal of Asthma. ZYFLO CR was approved by the U.S. Food and DrugAdministration (FDA) on May 30, 2007. Critical Therapeutics,together with it...

OREXIGEN Therapeutics Announces Sustained-Release Formulation of Zonisamide Shows Improved Tolerability When Compared to Immediate Release Formulation

Orexigen(TM) is evaluating zonisamide SR as a novel component inEMPATIC(TM) Phase IIb obesity trial SAN DIEGO, June 07, 2007 /PRNewswire-FirstCall/ -- Orexigen(TM)Therapeutics, Inc. , a biopharmaceutical company focused on thetreatment of central nervous system disorders with an initial focuson obesity, today announced results from a Phase I trial evaluatingsafety and pharmacokinetics of...

New Research Confirms the Benefit of Extended-Release Dipyridamole Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk Patients

Aggrenox® (Asasantin® Retard) considered by many asfirst-line in secondary stroke prevention INGELHEIM, Germany, 31 May 2007 - New data presented today at the16th European Stroke Conference in Glasgow confirm that therapywith dipyridamole plus ASA (extended-release dipyridamole plus ASAis marketed as Aggrenox® or Asasantin® Retard) is superiorto ASA* alone in...

Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents

SAN DIEGO, May 23, 2007 /PRNewswire-FirstCall/ -- Shire plcannounced today the positive results of studies of theinvestigational medication guanfacine extended release (GXR,previously referred to as SPD503), a selectivealpha-2A-adrenoceptor agonist. These data from two short-term phaseIII placebo-controlled studies and two long-term phase IIIopen-label studies, presented at the 2007 Amer...

Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)

First Release of Data for New Combination PARSIPPANY, NJ(May 21, 2007) -- Combining the calcium channel blockeramlodipine besylat...

Blood Levels of Paliperidone Extended-Release Tablets are Not Increased by Common Antidepressant

Study shows paroxetine produced no significant drug interactionwith paliperidone ER SAN DIEGO, May 22, 2007 /PRNewswire/ -- After administration ofpaliperidone extended-release (ER) tablets, blood levels of thedrug were not affected when given with a common antidepressant,according to new data presented today at the 160th Annual Meetingof the American Psychiatric Association. Paroxetine,...

New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia

--Study Used To Support FDA Approval of SEROQUEL XR-- WILMINGTON, Del., May 22, 2007 /PRNewswire-FirstCall/ --AstraZeneca today announced that two analyses from a large-scalestudy that investigated the efficacy of SEROQUEL XR(TM) (quetiapinefumarate) Extended-Release Tablets, a once-daily medicine for thetreatment of schizophrenia in adult patients, were presented todayat the annual meeti...

Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years

Trial results report no new stent thrombosis after two years inhigh-risk patient population NATICK, Mass., and BARCELONA, Spain, May 22, 2007/PRNewswire-FirstCall/ -- Boston Scientific Corporation todayannounced four-year follow-up data from its TAXUS VI clinicaltrial. The data demonstrated that the safety and efficacy benefitsassociated with a moderate-release formulation of the TAXUS(R)...

Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)

First Release of Data for New Combination PARSIPPANY, N.J., May 21, 2007 /PRNewswire/ -- Combining thecalcium channel blocker amlodipine besylate with the angiotensinreceptor blocker olmesartan medoxomil, produced significant meanreductions in seated systolic and diastolic blood pressure inpatients with hypertension, according to data presented at theAmerican Society of Hypertension's Twe...

Alpharma Presents Positive Pharmacokinetic Study Results of Its Investigational Abuse-Deterrent, Extended-Release Opioid

BRIDGEWATER, N.J., May 03, 2007 /PRNewswire-FirstCall/ --Alpharma Inc. , a leading global specialty pharmaceutical companythrough its Pharmaceuticals Division, this week presented positiveresults of a pharmacokinetic study of its investigationalabuse-deterrent, extended-release opioid at the 26th annualscientific meeting of the American Pain Society in Washington, D.C.The data demonstrat...

Insmed Releases Positive Results from Iplex Phase II HIV-Associated Adipose Redistribution Syndrome Clinical Study

RICHMOND, Va.--(BUSINESS WIRE)--Apr 30, 2007 - Insmed Inc.,(Nasdaq:INSM) today announced positive results from a Phase IIinvestigator-sponsored clinical study of the company's drugIPLEX(TM) in HIV-infected patients affected with HIV-associatedAdipose Redistribution Syndrome (HARS). Preliminary results from the study, being conducted at theUniversity of California, San Francisco, showed th...

New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting

ADDISON, Texas, April 19, 2007 /PRNewswire/ -- New clinicaltrial results for heart transplant patients will be released at theupcoming International Society for Heart and Lung Transplantation(ISHLT) 27th Annual Meeting and Scientific Sessions at the HiltonSan Francisco, April 25-28, 2007. Results show promise for efficacyand safety of immunosuppression therapy and lower incidences ofacut...

Once Daily, Extended-Release Ropinirole Improves Parkinson's Symptoms in Patients not Optimally Controlled With Levodopa

'Off' Time Reduced By an Average of More Than Two Hours Per Day RESEARCH TRIANGLE PARK, N.C., April 02, 2007 /PRNewswire/ --Adding the once daily, investigational medication REQUIP(R)(ropinirole HCl) XL 24-Hour(TM) Extended-Release Tablets toParkinson's patients' existing levodopa (L-dopa) therapysignificantly reduced 'off' time, allowing patients to continuetheir daily activities for a l...

State of Diabetes in Pittsburgh: Pittsburgh Business Group on Health Releases Report

Good News: Percentage of Working Age People with Diabetes, Hospitaland Professional Charges Lower Than Both PA and National Averages PITTSBURGH, April 02, 2007 /PRNewswire-FirstCall/ -- ThePittsburgh Business Group on Health (PBGH) announced today therelease of a new report on the prevalence, costs and quality ofcare for people with Type 2 diabetes. The inaugural Pittsburgh Type2 Diabetes...

Seroquel Sustained Release Schizophrenia Data Presented at ECP Congress in Madrid

LONDON, March 18, 2007-AstraZeneca today announced clinicaltrial data for Seroquel sustained release formulation (quetiapinefumarate sustained release), at the European Congress of Psychiatry(ECP) in Madrid. The data demonstrated that the SEROQUEL®sustained release formulation (quetiapine fumarate sustainedrelease), administered once daily, significantly improved symptomsassociated w...

Newly Released Canadian Data Links Vaccines with Pervasive Developmental Disorder

National Autism Association calls 2006 Pediatrics study fatallyflawed CHICAGO, March 07, 2007 /PRNewswire-USNewswire/ -- New findingspresented yesterday at a National Autism Association meetingbolster claims that vaccines may play a role in the development ofautism spectrum disorders. David Ayoub, MD presented datasuggesting a correlation between mercury- containing vaccines andrates of...